HIV persistence remains one of the major challenges in developing a complete cure for HIV infection. Although antiretroviral therapy can suppress viral replication and help people maintain their health, the virus can remain hidden in long-lived cells and tissues. Understanding viral reservoirs, latency, immune responses, and treatment limitations is essential for studying future HIV eradication strategies.
One important reason is the ability of HIV to establish persistent infections. Even when treatment reduces the amount of virus in the bloodstream to undetectable levels, some infected cells continue to carry viral genetic material. These hidden sources of infection make it difficult to eliminate the virus entirely. Researchers continue to investigate the biological mechanisms responsible for HIV persistence and potential approaches to overcoming them.
HIV persistence refers to the ability of the virus to remain in the body despite effective antiretroviral treatment. After entering a susceptible immune cell, HIV converts its RNA into DNA using an enzyme called reverse transcriptase. This viral DNA can integrate into the host cell's genetic material, creating a long-term source of infection.
Some infected cells become inactive or enter a resting state. In these cells, HIV can remain dormant without producing significant amounts of new virus. Antiretroviral medications primarily target different stages of active viral replication, making it difficult for them to eliminate these inactive infected cells.
These hidden populations are known as HIV reservoirs. They are a major focus of research because they can contribute to viral rebound when treatment is discontinued.
Important characteristics of HIV reservoirs include:
Long-lived infected cells: Certain immune cells can survive for extended periods while carrying integrated HIV DNA.
Viral latency: HIV may remain inactive inside infected cells without producing new viral particles.
Tissue reservoirs: HIV genetic material can persist in different tissues, including lymph nodes and the central nervous system.
Clonal expansion: Some infected cells multiply, producing populations of cells that carry the same integrated viral DNA.
Viral reactivation: Dormant HIV can become active again under certain biological conditions.
Understanding these reservoirs helps researchers explain why maintaining viral suppression does not necessarily mean that HIV has been completely removed from the body.
Developing a strategy to eliminate HIV requires addressing several biological and treatment-related challenges. The virus can integrate its genetic material into human cells, remain hidden from immune surveillance, and develop genetic variations that complicate treatment research.
One significant challenge is identifying and targeting all infected cells. HIV reservoirs are distributed across different tissues, and some infected cells may be present at extremely low levels. Current testing methods cannot always detect every source of persistent infection.
Another challenge involves the complexity of the immune response. Although the immune system can recognize and control many infections, HIV has developed mechanisms that help it evade immune detection. This makes it difficult for natural immune responses to remove every infected cell.
Researchers are investigating several scientific approaches:
Latency reversing agents: These compounds aim to activate dormant HIV so that infected cells can become visible to immune responses or other elimination strategies.
Immune-based therapies: Researchers are studying broadly neutralizing antibodies and engineered immune cells to improve the recognition of HIV-infected cells.
Gene editing: Technologies such as CRISPR are being investigated for their potential to target integrated HIV genetic material.
Therapeutic vaccines: These vaccines aim to strengthen immune responses against HIV in people already living with the infection.
Combination approaches: Combining different strategies may help address multiple mechanisms responsible for viral persistence.
Each approach has limitations involving effectiveness, safety, delivery, and the ability to reach hidden viral reservoirs. Additionally, treatment interruptions can lead to viral rebound, which is why people living with HIV should continue prescribed antiretroviral therapy unless their healthcare provider advises otherwise.
Ongoing research into HIV persistence is helping scientists understand the biological barriers to viral eradication and evaluate new therapeutic strategies.